Sequence 4 from Patent US 20020137896

General Information


DRACP ID  DRACP01223

Peptide Name   Sequence 4 from Patent US 20020137896

Sequence  PIRLSKEKINDLLQRSQGDLTSSQHEIVHFTDVFIAGSGPISCTYARHIIDNTSTTK

Sequence Length  57

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01223

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C276H446N80O89S

Absent amino acids  MW

Common amino acids  IST

Mass  734017

Pl  7.62

Basic residues  9

Acidic residues  6

Hydrophobic residues  17

Net charge  3

Boman Index  -11727

Hydrophobicity  -38.6

Aliphatic Index  88.95

Half Life 
  Mammalian: >20 hour
  Yeast: >20 hour
  E.coli: ?

Extinction Coefficient cystines  1490

Absorbance 280nm  26.61

Polar residues  20

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2002/0137896 A1

Patent Title  Antitumor protein and gene encoding same.

Other Iinformation  Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status: Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004

Other Published ID  US6291648  US6762296 




DRACP is developed by Dr.Zheng's team.